Keywords: Shire, MMX mesalamine, Diverticulosis, Ph III

Shire takes hit as bowel disease drug Lialda fails in Ph III trial

Article | 02 April 2012

Print This

The shares of Ireland-headquartered Shire (LSE: SHP) dropped 4.9% to £20.14 in mid afternoon trading last Friday, after it announced top-line ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in